A Developer’s Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10-Reference-Cited by-同舟云学术

A Developer’s Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10

Published:2022-03-24 Issue:4 Volume:42 Page:285-300
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Choi Dasom^ORCID,Lee Soohyun^ORCID,Kim Seungmin^ORCID,Yoon Sangwook^ORCID

Funder

Celltrion Healthcare

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-022-01133-x.pdf

Reference82 articles.

1. US Food and Drug Administration. Rituxan BLA approval letter. 1997. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1997/ritugen112697L.htm. Accessed 20 Jan 2022.

2. European Medicines Agency. MabThera scientific discussion. 2006. https://www.ema.europa.eu/en/documents/scientific-discussion/mabthera-epar-scientific-discussion_en.pdf. Accessed 20 Jan 2022.

3. European Medicines Agency. MabThera summary of product characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Accessed 20 Jan 2022.

4. European Medicines Agency. Truxima summary of product characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/truxima-epar-product-information_en.pdf. Accessed 20 Jan 2022.

5. US Food and Drug Administration. Truxima BLA approval letter. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761088Orig1s000ltr.pdf. Accessed 20 Jan 2022.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience;Internal and Emergency Medicine;2023-02-24